drugset / Trial / NCT05452343
A Study of CM310 in Subjects With Chronic Pruritus
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a multi-center, randomized, double blind, placebo-controlled Phase II study to evaluate the efficacy and safety of CM310 in subjects with chronic pruritus of unknown origin.
Timeline
- Start
- 2022-08-30
- Primary completion
- 2024-03-01
- Completion
- 2024-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CM310 | Monoclonal antibody | 300 mg | Subcutaneous |
Indications
No indication recorded.